Can a PET-CT Scan Detect Cancer — Anywhere in the Body?

The skull is scanned as part of most whole-body protocols, but PET-CT is not reliable for detecting brain metastases. The brain uses glucose constantly and at a high rate, so the tracer accumulates throughout normal brain tissue. A small tumour deposit produces only a small increase on top of that high background, making it difficult to see. MRI with contrast is the standard investigation when brain spread is a concern. Your oncologist will order one alongside or instead of the PET-CT if the brain is a priority for your situation.

The standard field covers the regions where most solid tumours spread — lymph node chains in the chest, abdomen, pelvis, and upper thighs account for the large majority of metastatic sites. Including the calves and feet in every scan would add radiation exposure and scan time without benefiting most patients. When cancer involves the lower leg — a melanoma on the foot or a bone tumour in the calf, for example — the field is extended to cover it. Your oncologist or the radiologist setting the protocol decides this before the scan begins.

Yes, and understanding when helps you ask the right questions. Small tumour deposits can fall below the scan's resolution — your oncologist can tell you whether this is a concern for your specific situation. Some cancers absorb little glucose even when active: certain prostate cancers, some carcinoid tumours, mucinous tumours, and low-grade lymphomas give less information on FDG PET-CT. The scan is also less reliable in the brain and in areas recently affected by surgery or infection, where healing tissue also absorbs tracer. PET-CT is always interpreted alongside your clinical picture and other tests, not as a single definitive answer.

A CT scan shows anatomy — the size and shape of structures. An MRI shows anatomy in greater detail, particularly for soft tissue such as brain, spinal cord, and muscle. A PET-CT adds metabolic information: it shows which areas are absorbing more glucose, which can distinguish an active tumour from scar tissue even when both look similar on a plain CT. That combination makes PET-CT useful for staging and for assessing treatment response. It does not replace CT or MRI for every question — each tool answers a different one, and your oncologist will choose based on what needs to be known.

FDG-avid means the area absorbed more tracer than surrounding tissue. Many things other than cancer do this: active infections, inflammatory conditions, healing tissue after a procedure, and some benign tumours can all appear FDG-avid on a scan. The report flags the finding; your oncologist decides what it means in your specific context. A biopsy is sometimes needed to be certain. Do not read a single finding on a scan report in isolation — the radiologist's written conclusion and your oncologist's interpretation together are what matters.

PET-CT scans coordinated through CION are performed at partner imaging centres in Hyderabad. The total visit takes several hours, though most of that is resting time after the injection rather than time in the scanner itself. You will need to fast beforehand and avoid strenuous activity on the day, because muscle activity causes muscles to absorb the tracer and can affect the images. The detailed timing and fasting instructions come from the imaging centre before your appointment. Follow them exactly, and contact the centre in advance if you have diabetes or take insulin.